Case Report
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Apr 26, 2022; 10(12): 3801-3807
Published online Apr 26, 2022. doi: 10.12998/wjcc.v10.i12.3801
Anti-programmed death 1 antibody in the treatment of coexistent Mycobacterium fortuitum and lung cancer: A case report
Cui-Cui Zhang, Peng Chen
Cui-Cui Zhang, Peng Chen, Department of Thoracic Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China
Author contributions: Zhang CC and Chen P composed the article.
Informed consent statement: Written informed consent has been provided by the patient’s next-of-kin to have the case details and any accompanying images published.
Conflict-of-interest statement: All the authors hereby declare that they do not have any competing interests with regard to the manuscript submitted here for review.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Peng Chen, MD, Chief Doctor, Professor, Department of Thoracic Oncology, Tianjin Medical University Cancer Institute and Hospital, West Huanhu Rd, Tianjin 300060, China. pengchentj@126.com
Received: June 4, 2021
Peer-review started: June 4, 2021
First decision: September 1, 2021
Revised: September 26, 2021
Accepted: March 6, 2022
Article in press: March 6, 2022
Published online: April 26, 2022
Processing time: 321 Days and 10 Hours
Core Tip

Core Tip: The clinical experience in the application of immune checkpoint inhibitors is scarce for lung cancer patients with pulmonary tuberculosis, and lung cancer with nontuberculous mycobacterium (NTM) is even more rare. We present the case of a patient who had both lung cancer and NTM. NTM was stable, and the tumors shrank after treatment with immune checkpoint inhibitors. It provides some reference for the treatment of coexistent lung cancer with NTM.